Back

Detection and management of clinically relevant drug-drug interactions with direct oral anticoagulants in ambulatory care: a prospective interventional study in community pharmacies

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Oral anticoagulation: minimising bleeding Anticoagulants ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Andreas Capiau

Ghent University, Ghent (Belgium)

5 More presentations in this session

Presentation thumbnail
Outcomes with oral anticoagulation resumption or discontinuation after an anticoagulation-related event in patients with atrial fibrillation
Doctor G. Denas (Motta Di Livenza, IT)
Abstract Slides Video
Presentation thumbnail
Effectiveness of high- versus low-dose four-factor prothrombin complex concentrate on hemostasis and thromboembolism in patients with oral factor Xa inhibitor-associated intracranial hemorrhage
Doctor W. Baker (Storrs, US)
Abstract Slides Video
Presentation thumbnail
DNA methylation of ADAMTS7 gene promoter in direct oral anticoagulant-induced bleeding in patients with atrial fibrillation
Miss N. Atzemian (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Factor XI inhibitors in early clinical trials: a meta-analysis
Doctor M. Galli (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Comparison of Antithrombotic Regimens after Left Atrial Appendage Occlusion: A Systematic Review and Network Meta-analysis
Doctor L. KUBRUSLY (Curitiba, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Oral anticoagulation: minimising bleeding

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Thrombocheck: a drug-drug interactions guide for cardiologists prescribing antithrombotic therapy
thumbnail
Congress Presentation
Drug interactions in incident NOACs users and risk of bleeding
thumbnail
Congress Presentation
Drug-drug interactions of NOACs with comedication: prevalence and implications for adverse events in patients with atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources